跳转至内容
Merck
  • The liver-selective NO donor, V-PYRRO/NO, protects against liver steatosis and improves postprandial glucose tolerance in mice fed high fat diet.

The liver-selective NO donor, V-PYRRO/NO, protects against liver steatosis and improves postprandial glucose tolerance in mice fed high fat diet.

Biochemical pharmacology (2014-12-24)
Edyta Maslak, Piotr Zabielski, Kamila Kochan, Kamil Kus, Agnieszka Jasztal, Barbara Sitek, Bartosz Proniewski, Tomasz Wojcik, Katarzyna Gula, Agnieszka Kij, Maria Walczak, Małgorzata Baranska, Adrian Chabowski, Ryan J Holland, Joseph E Saavedra, Larry K Keefer, Stefan Chlopicki
摘要

There is an unmet medical need for novel NAFLD treatments. Here we have examined the effects of liver-selective NO donor (V-PYRRO/NO) as compared with metformin on hepatic steatosis and glucose tolerance in mice fed high fat diet. Effects of V-PYRRO/NO (5 mgkg(-1)) or metformin (616 mgkg(-1)) were examined in C57BL/6J mice fed high fat diet (HF, 60 kcal% fat). Quantitative determination of steatosis, liver fatty acid composition and western blot analysis of selected proteins involved in mitochondrial biogenesis, fatty acid de novo synthesis and oxidation, triacylglycerols and cholesterol transport from the liver were performed. Liver NOx and nitrate concentration and blood biochemistry were also analyzed. V-PYRRO/NO and metformin reduced liver steatosis with simultaneous reduction of total liver triacylglycerols, diacylglycerols and ceramides fraction and reversed HF-induced decrease in UFA/SFA ratio. V-PYRRO/NO substantially improved postprandial glucose tolerance, while the effect of metformin was modest and more pronounced on HOMA IR index. The anti-steatotic mechanism of V-PYRRO/NO was dependent on NO release, differed from that of metformin and involved improved glucose tolerance and inhibition of de novo fatty acid synthesis by Akt activation and ACC phosphorylation. In turn, major mechanism of metformin action involved increased expression of proteins implicated in mitochondrial biogenesis and metabolism (PGC-1α, PPARα, COX IV, cytochrome c, HADHSC). V-PYRRO/NO acts as a liver-specific NO donor prodrug affording pronounced anti-steatotic effects and may represent an efficient, mechanistically novel approach to prevent liver steatosis and insulin resistance.

材料
货号
品牌
产品描述

Sigma-Aldrich
乙腈, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
甲醇, suitable for HPLC, ≥99.9%
Sigma-Aldrich
纯乙醇, for molecular biology
Sigma-Aldrich
盐酸, ACS reagent, 37%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
纯乙醇, 200 proof, ACS reagent, ≥99.5%
Sigma-Aldrich
乙腈, HPLC Plus, ≥99.9%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
纯乙醇, 200 proof
Sigma-Aldrich
盐酸, ACS reagent, 37%
Sigma-Aldrich
甲醇, HPLC Plus, ≥99.9%
Sigma-Aldrich
氯化氢 溶液, 4.0 M in dioxane
Sigma-Aldrich
纯乙醇, 200 proof, meets USP testing specifications
Sigma-Aldrich
乙腈, ACS reagent, ≥99.5%
Sigma-Aldrich
D -(+)-葡萄糖 溶液, 45% in H2O, sterile-filtered, BioXtra, suitable for cell culture
Sigma-Aldrich
甲酸铵, reagent grade, 97%
Sigma-Aldrich
甲醛 溶液, for molecular biology, 36.5-38% in H2O
Sigma-Aldrich
纯乙醇, for molecular biology
Sigma-Aldrich
乙腈, ≥99.9% (GC)
Sigma-Aldrich
盐酸 溶液, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
乙腈, suitable for HPLC, gradient grade, ≥99.9%
SAFC
甲醛 溶液, contains 10-15% methanol as stabilizer, 37 wt. % in H2O
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Sigma-Aldrich
盐酸, meets analytical specification of Ph. Eur., BP, NF, fuming, 36.5-38%
Sigma-Aldrich
D -(+)-葡萄糖 溶液, 100 g/L in H2O, sterile-filtered, BioXtra, suitable for cell culture
Sigma-Aldrich
甲醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
盐酸, 37 wt. % in H2O, 99.999% trace metals basis
Sigma-Aldrich
盐酸, 36.5-38.0%, BioReagent, for molecular biology
Sigma-Aldrich
氯化氢 溶液, 2.0 M in diethyl ether
Sigma-Aldrich
盐酸, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., fuming, ≥37%, APHA: ≤10